Rapid Dose Therapeutics Enters Supplier and Purchase Agreement with a Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products

Rapid Dose Therapeutics Enters Supplier and Purchase Agreement with a Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products




Rapid Dose Therapeutics Enters Supplier and Purchase Agreement with a Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products

 

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company focused on health and wellness leveraging an innovative, proprietary oral delivery platform today announced that they have entered into a supplier and purchase agreement with a leading Gas and Convenience Store Retailer.

RDT’s QuickStrip Sleep (melatonin) and QuickStrip Energy (caffeine) products will be available at 300 retail stores across Ontario beginning this October followed by an additional 400 locations throughout Ontario. These unique products will be featured in a new innovation section within each store.

“Gaining exposure of our QuickStrip branded products in this prominent Convenience Retail Chain is an excellent win for our team as it will help to quickly drive market awareness of our innovative offerings,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “This agreement broadens the consumer penetration of QuickStrip products, leveraging this leading Retailer’s expansive network of stores.”

Mark continues, “Additionally, further updates will be made over the coming weeks as new distribution deals are announced.”

Information about RDT’s QuickStrip products and searchable database of retail locations can be found at https://quickstrip.life/.

The Supplier and Purchase Agreement was signed on August 24, 2022 with the initial purchase order dated September 15, 2022.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

RDT Investors:
Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052

Media:
Dara Willis

dara@dwcomm.ca
416-836-9272